华蟾素联合希罗达/奥沙利铂治疗进展期胃癌

目的评价华蟾素联合希罗达/奥沙利铂方案治疗进展期胃癌的临床疗效和不良反应。方法 60例进展期胃癌患者随机分为2组：实验组30例,采用华蟾素＋希罗达/奥沙利铂方案化疗;对照组30例,采用奥沙利铂联合ELF（足叶乙甙＋亚叶酸钙＋5-氟尿嘧啶）方案。比较2组的治疗效果和不良反应发生情况。结果实验组完全缓解（CR）5例,部分缓解（PR）18例,总缓解率为77%,中位疾病进展时间为7.2个月,中位生存时间为11.5个月;主要毒副反应为白细胞减少和手足综合征。对照组CR 4例,PR 12例,总缓解率为53%,中位疾病进展时间为5.8个月,中位生存时间为9.5个月;主要的不良反应为白细胞减少。2组均无Ⅳ～Ⅴ度不良反应。2组临床症状及生活质量改善情况比较有显著性差异（P均〈0.01）。实验组癌症疼痛缓解率明显高于对照组（P〈0.01）,免疫指标（NK细胞活性,及CD3＋、CD4＋、CD8＋阳性细胞百分率,CD4＋/CD8＋比值）改善情况较对照显著提高（P均〈0.05）。结论华蟾素联合希罗达/奥沙利铂联合化疗治疗进展期胃癌疗效确切,不良反应较低,能显著提高机体免疫力,提高患者生存质量和化疗耐受性。

Cinobufagin injection combined chemotherapeutics in advanced gastric carcinoma

Objective It is to investigate the clinical efficacy and side effect of cinobufagin injection combined with capecitabine plus oxaliplatin regimen in patients with advanced gastric carcinoma. Methods Sixty patients with advanced gastric carcinoma were randomly divided into two groups ： Test group （n = 30） was received cinobufagin injection combined with capecitabine plus oxaliplatin regimen chemotherapy ; Control group （ n = 30） was received oxaliplatin plus calcium folinate and 5 - Fu and etoposide regimen chemotherapy alone. The efficacy and side effect were compared between both groups. Results In test group, the total response rate was 77% （5 complete responses and 18 partial responses） , the median time to progression was 7.2 months and the median overall survival was 11.5 months; and the most common side effect was leucopenia （43%） and hand -foot syndrome （23%）. In control group, the total response rate was 53% （4 complete responses and 12 partial responses）, the median time to progression was 5.8 months and the median overall survival was 9.5 months; and the most common side effect was leucopenia （57%）. No grade IV and V side effect was observed in both groups. The life quality and clinical symptom of the patients in test group were improved more significantly than those in control group （ P 〈 0.01 ）. Cancer pain relief rate in test group was significantly higher thanin control group （ P 〈 0.01 ）. The immunity function in test group were significantly higher than in control group （ P 〈 0.05 ）. Conclusion Conclusions ： The cinobufagin injection combine with capecitabine plus oxaliplatin regimen shows good efficacy and acceptable safety in patients with advanced gastric cancer, can enhance the immune function and improve life quality.